Baker McKenzie Switzerland — along with Baker McKenzie lawyers from the UK, US, Germany and further European jurisdictions — advised DocMorris AG ("DocMorris") on its successful rights offering with gross proceeds of CHF 208 million. The proceeds will be used to finance the planned medium-term growth in the prescription medicines (Rx) business, including incrementally targeted Rx marketing spend, as well as a potential repayment of the CHF 95 million convertible bond in September 2026.
The company has issued 36,182,790 new registered shares on 21 May 2025, which were listed on SIX Swiss Exchange on 22 May 2025 and settled on 26 May 2025. The capital increase was accompanied by a nominal value reduction from CHF 30.00 to CHF 0.01.
Baker McKenzie acted as legal counsel to DocMorris on all aspects of the rights offering. A transnational syndicate consisting of three financial institutions carried out the rights offering, which was fully underwritten and further supported by a selling agent.
Swiss Capital Markets Partners Matthias Courvoisier and Yves Mauchle led the Baker McKenzie team, which included the following members:
- Baker McKenzie Switzerland (Swiss Capital Markets, Corporate and Tax): Jan Lusti, Kiara Sharifi, Jonas Zürrer, Sadia Raja, Chiara Pedrazzetti, Andrea Bolliger, Nathan Bouvier
- Baker McKenzie London (US Capital Markets): Adam Farlow, Charles Farnsworth
- Baker McKenzie New York (US Tax): Paul de Pasquale, Jayshree Narendran
- Baker McKenzie Frankfurt (EU and German Regulatory): Dr. Frank Pflüger